MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Clinical trials for MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets rare lymphoma in early trial
Disease control Recruiting nowThis phase 1 trial is testing whether adding the drug ruxolitinib to standard CHOP chemotherapy is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare type of non-Hodgkin lymphoma. About 20 adults will receive the combination to find…
Matched conditions: MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Lymphoma Patients' vaccine response under microscope
Knowledge-focused Recruiting nowThis study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells over time in 200 participants with different types of lymphoma. The goal is to understand how lymphoma and its treatment…
Matched conditions: MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC